Global Severe Combined Immunodeficiency Market, By Type (Classical X-linked SCID, ADA deficiency SCID), Treatment (Medication, Gene Therapy, Stem Cell Therapy, Enzyme Therapy, Others), Diagnosis (Blood Tests, New-born Screening Test, Genetic Tests, Others), Symptoms (Failure to Thrive, Ear Infections, Chronic Diarrhea, Sinusitis, Oral Thrush, Meningitis, Skin Rashes, Pneumonia, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Severe Combined Immunodeficiency Market Analysis and Size
Severe combined immunodeficiency are rare forms of genetic disorders that can be fatal for an infant if not treated promptly. Rise in awareness about screening and diagnosis of these disorders is projected to augment the global severe combined immunodeficiency treatment market. Availability of drugs and immune-related treatments will likely to augment the growth of the severe combined immunodeficiency market in the projected timeframe of 2023 to 2030. Technological advancements in the screening technique is expected to boost the growth of the global severe combined immunodeficiency treatment market. Adoption of stem cell therapy, gene therapy, and other therapies is also likely to propel the global market. Moreover, antibody infusion and bone marrow transplant are commonly recommended for the treatment of children with severe combined immunodeficiency.
Data Bridge Market Research analyses that the severe combined immunodeficiency market which was USD 196.50 million in 2022, is expected to reach USD 423.5 million by 2030, and is expected to undergo a CAGR of 10.4% during the forecast period. This indicates that the market value. “Hospital” dominates the end user segment of the severe combined immunodeficiency market owing to the increasing cases in hospitals. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Severe Combined Immunodeficiency Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Classical X-linked SCID, ADA deficiency SCID), Treatment (Medication, Gene Therapy, Stem Cell Therapy, Enzyme Therapy, Others), Diagnosis (Blood Tests, New-born Screening Test, Genetic Tests, Others), Symptoms (Failure to Thrive, Ear Infections, Chronic Diarrhea, Sinusitis, Oral Thrush, Meningitis, Skin Rashes, Pneumonia, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AbbVie Inc. (Ireland), Merck Sharp & Dohme Corp. (U.S.), Pfizer Inc. (U.S.) ,GlaxoSmithKline plc. (U.K.), Melinta Therapeutics LLC (U.S.), Basilea Pharmaceutica Ltd. (Switzerland), Tetraphase Pharmaceuticals (U.S.), Paratek Pharmaceuticals, Inc. (U.S.), Nabriva Therapeutics plc (Ireland), Spero Therapeutics (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), SHIONOGI & Co., Ltd. (Japan), Cumberland Pharmaceuticals Inc. (U.S.), Eli Lilly and Company (U.S.), among others
|
|
Market Opportunities
|
|
Market Definition
Severe combined immunodeficiency (SCID) is rare, inherited disorders that result in major immune system abnormalities. It is caused due to the changes in the different genes responsible for the development and functioning of infection-fighting immune cells. SCID is a type of primary immunodeficiency disease which is characterized by chronic diarrhea, failure to thrive, ear infections, sinusitis, oral thrush, meningitis, skin rashes, pneumonia, among others. These disorders are considered life-threatening or fatal mostly in the first two years of a child’s life.
Global Severe Combined Immunodeficiency Market Dynamics
Drivers
- Increasing Prevalence of Severe Combined Immunodeficiency
The prevalence of severe combined immunodeficiency (SCID) is a critical factor that can influence the market for SCID treatments. SCID is a rare genetic disorder characterized by a severely compromised immune system, and its prevalence can vary by region and population
The prevalence of SCID can vary by region and population. Some genetic mutations that cause SCID are more prevalent in certain ethnic or geographic groups, which can drive the demand for acute severe combined immunodeficiency market
Moreover, population growth can lead to an increase in the number of SCID cases. A larger patient population can potentially drive market growth as the demand for treatments increases, necessitating the need for demand of treatment
- Increase in Early Diagnosis or Screening of the Disorder
Screening or early diagnosis plays an important role in saving the lives of infants. Addition of the IDF SCID Newborn Screening Campaign in the newborn screening panel of the U.S. resulted in higher awareness about the diagnosis of SICD. This can foster the demand for diagnosis of severe combined immunodeficiency cases across the globe
According to the Immune Deficiency Foundation, 13 different genetic defects can cause severe combined immunodeficiency in infants, leading to serious infections. According to scientists, gene therapy offers promising treatment for this disorder. ADA-SCID is a rare inherited disorder, also known as bubble syndrome, caused by mutation in the adenosine deaminase (ADA) gene. This type of SCID is the second most prevalent form of the disorder
Moreover, the implementation of newborn screening programs in various countries has led to the early diagnosis of SCID. Early detection allows for timely intervention and treatment, potentially improving patient outcomes and increasing the demand for SCID therapies. This shift is expected to boost the demand for severe combined immunodeficiency market
- Increasing Healthcare Expenditure
Greater healthcare expenditure, both by governments and private entities, can provide healthcare facilities with more resources to invest in advanced severe combined immunodeficiency equipment and treatments. Thus, demand for treatment has driven the development of new technologies which further fuel the growth during the severe combined immunodeficiency market in the forecast period.
Moreover, Growing awareness among healthcare providers, caregivers, and the general public about SCID and its consequences has led to more timely diagnoses and treatments. Increased awareness can drive the demand for SCID therapies. Increasing awareness about the importance of diagnosis and treatment of severe combined immunodeficiency can lead to more patients seeking medical care, which will further act as driver that will lead to the growth of the severe combined immunodeficiency market in the above mentioned projected timeframe
Opportunities
- Rising Collaborations and Investments by Leading Players
Increasing collaborations between pharmaceutical companies, research institutions, and healthcare organizations have facilitated research and development efforts for SCID treatments. These collaborations can accelerate the development and commercialization of new therapies. This will extend profitable opportunities for the severe combined immunodeficiency market players in the forecast period of 2023 to 2030
In addition, the improvements in healthcare infrastructure, particularly in emerging markets, have increased access to SCID treatments. Expansion of healthcare services and insurance coverage, which will further contribute by generating immense opportunities that will further expand the market's growth rate in the future
Restraint/Challenge
- High Cost Associated with the Treatment
On the other hand, high cost associated with the treatment, especially gene therapies, which is a highly specialized and resource-intensive process. Ensuring affordability and equitable access to these treatments will likely to act as market restraints factor for the growth of the acute abdomen trauma market in the above mentioned projected timeframe. Moreover, developing new treatments for rare diseases such as SCID can be expensive. The cost of research, clinical trials, and manufacturing can be substantial will become the biggest and foremost challenge for the growth of the market in the forecast period of 2023 to 2030
This severe combined immunodeficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the severe combined immunodeficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Development
- In September 2020, DJO will release the DonJoy X-ROM Post-Op Knee Brace. The product is stated to be one of the most advanced range of motion (ROM) protection, with an improved user-friendly design for quicker and faster application and adjustment. The X-ROM brace aids patients in their recovery after ACL reconstruction and other knee procedures. It increases comfort, stability, and confidence
Global Severe Combined Immunodeficiency Market Scope
The severe combined immunodeficiency market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Classical X-linked SCID
- ADA deficiency SCID
Treatment
- Medication
- Antibiotics
- Immune Globulin Replacement Therapy
- Antifungals
- Gene Therapy
- Stem Cell Therapy
- Enzyme Therapy
- Others
Diagnosis
- Blood Tests
- New-born Screening Test
- Genetic Tests
- Others
Symptoms
- Failure to Thrive
- Ear Infections
- Chronic Diarrhea
- Sinusitis
- Oral Thrush
- Meningitis
- Skin Rashes
- Pneumonia
- Others
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Intravenous
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Severe Combined Immunodeficiency Market Regional Analysis/Insights
The severe combined immunodeficiency market is analyzed and market size insights and trends are provided by type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel
The countries covered in the severe combined immunodeficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the severe combined immunodeficiency market due to the presence of major key players, the high adoption rate of stem cell therapy and the well-developed healthcare infrastructure in this region.
Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 owing to the increasing awareness about screening of rare disorders, advancement of healthcare sector and rising investments for clinical trials in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The severe combined immunodeficiency market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products severe combined immunodeficiency Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the severe combined immunodeficiency market. The data is available for historic period 2010 to 2021.
Competitive Landscape and Severe combined immunodeficiency market Share Analysis
The severe combined immunodeficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to severe combined immunodeficiency market.
Some of the major players operating in the severe combined immunodeficiency market are:
- AbbVie Inc. (Ireland)
- Merck Sharp & Dohme Corp. (U.S.)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc. (U.K.)
- Melinta Therapeutics LLC (U.S.)
- Basilea Pharmaceutica Ltd. (Switzerland)
- Tetraphase Pharmaceuticals (U.S.)
- Paratek Pharmaceuticals, Inc. (U.S.)
- Nabriva Therapeutics plc (Ireland)
- Spero Therapeutics (U.S.)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma ( India)
- Lupin (India)
- SHIONOGI & Co., Ltd. (Japan)
- Cumberland Pharmaceuticals Inc. (U.S.)
- Eli Lilly and Company (U.S.)
SKU-